This work gathers evidences that support the development of therapeutic modalities for the sepsis and other clinical conditions with high associate mortality, based on the use of synthetic peptides with anti-endotoxin and immunomodulator activity.

The study also collects important scientific contributions that contribute to the knowledge of pathophysiology of sepsis and of possibly protective mechanisms. These peptides protected the experimentation animals that had received a lethal inoculum of gram-negative bacteria and also polibacterial inoculum. This protective effect was evidenced by a significant survival increment regarding the animals which were not treated. One of these peptides (LALF 31-52) demonstrated to possess antiviral activity when inducing the production of Alpha and Gamma Interferon. It is also demonstrated the competition with the LBP (LPS Binding Protein) that is involved in the pathophysiology of diverse autoimmune diseases and the potential action of peptides as inhibitors of the bacterial translocation that constitutes a secondary damage in systemic syndromes of diverse etiologic origin.

This collective of authors have published 6 works, 5 in prestigious magazines, 11 presentations in international events, a patent granted in Cuba, United States and the European Union, and two requested patents.